Matetzky S, Freimark D, Chouraqui P, Rabinowitz B, Rath S, Kaplinsky E, Hod H
Heart Institute, Sheba Medical Center, Tel-Hashomer, Israel.
J Am Coll Cardiol. 1998 Mar 1;31(3):506-11. doi: 10.1016/s0735-1097(97)00538-x.
This study was designed to examine whether ST segment elevation in posterior chest leads (V7 to V9) during acute inferior myocardial infarction (MI) identifies patients with a concomitant posterior infarction and whether these patients might benefit more from thrombolysis.
Because the posterior wall is faced by none of the 12 standard electrocardiographic (ECG) leads, the ECG diagnosis of posterior infarction is problematic and has often remained undiagnosed, especially in the acute phase.
Eighty-seven patients with a first inferior infarction who were treated with recombinant tissue-type plasminogen activator were stratified according to the presence (Group A [46 patients]) or absence (Group B [41 patients]) of concomitant ST segment elevation in posterior chest leads V7 to V9.
Patients in Group A had a higher incidence of posterolateral wall motion abnormalities (p < 0.001) on radionuclide ventriculography, a larger infarct area (as evidenced by higher peak creatine kinase levels) (p < 0.02) and a lower left ventricular ejection fraction (LVEF) at hospital discharge (p < 0.008) than those in Group B. ST segment elevation in leads V7 to V9 was associated with a higher incidence of at least one of the following adverse clinical events: reinfarction, heart failure or death (p = 0.05). Although patency of the infarct-related artery (IRA) in Group A resulted in an improved LVEF at discharge (p < 0.012), LVEF was unchanged in Group B, regardless of the patency status of the IRA.
ST segment elevation in leads V7 to V9 identifies patients with a larger inferior MI because of concomitant posterolateral involvement. Such patients might benefit more from thrombolytic therapy.
本研究旨在探讨急性下壁心肌梗死(MI)时胸后壁导联(V7至V9)ST段抬高是否可识别合并后壁梗死的患者,以及这些患者是否可能从溶栓治疗中获益更多。
由于12个标准心电图(ECG)导联均未面向后壁,后壁梗死的ECG诊断存在问题,且常未被诊断出来,尤其是在急性期。
87例首次发生下壁梗死且接受重组组织型纤溶酶原激活剂治疗的患者,根据胸后壁导联V7至V9是否存在ST段抬高分为两组:A组(46例)存在ST段抬高,B组(41例)不存在ST段抬高。
与B组患者相比,A组患者放射性核素心室造影显示后外侧壁运动异常的发生率更高(p<0.001),梗死面积更大(肌酸激酶峰值水平更高可证明)(p<0.02),出院时左心室射血分数(LVEF)更低(p<0.008)。V7至V9导联ST段抬高与以下至少一种不良临床事件的发生率较高相关:再梗死、心力衰竭或死亡(p=0.05)。尽管A组梗死相关动脉(IRA)开通使出院时LVEF有所改善(p<0.012),但无论IRA是否开通,B组的LVEF均无变化。
V7至V9导联ST段抬高可识别因合并后外侧受累而梗死面积更大的下壁MI患者。这类患者可能从溶栓治疗中获益更多。